Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS)
100 Clinical Results associated with Novartis Pharma Vertriebs GmbH
0 Patents (Medical) associated with Novartis Pharma Vertriebs GmbH
100 Deals associated with Novartis Pharma Vertriebs GmbH
100 Translational Medicine associated with Novartis Pharma Vertriebs GmbH